They have 3 drugs in phase I trials isb 1342, isb 1442 and isb 2001. 1342 results are expected in q3 of the calender yr 2023.1442 results are also expected soon afterwards…
Both 1342 are designated orphan drugs by us fda .
These are mainly for blood cancer, for solid tumors they have 2 drugs in ind enabling studies.
Details on their website pipeline section.
| Subscribe To Our Free Newsletter |
